Ophthalmology-focused publications and findings on COVID-19: A systematic review

Ya-Ping Jin1,2*, Graham E Trope1, Sherif El-Defrawy1, Elin Y Liu3 and Yvonne M Buys1

Abstract
Purpose: To summarize COVID-19 research endeavors by ophthalmologists/researchers in terms of publication numbers, journals and author countries, and to detail key findings.
Methods: The LitCovid database was systematically reviewed for ophthalmology-focused COVID-19 articles. The quality of the evidence was assessed for articles investigating conjunctivitis in COVID-19 patients.
Results: There were 21,364 articles in LitCovid on June 12, 2020, of which 215 (1%) were ophthalmology-focused. Of articles on COVID-19 transmission, 3.3% were ophthalmology-focused. Ophthalmology-focused articles were published in 68 journals and originated from 25 countries. The top five countries publishing ophthalmology-focused articles (China, India, United States of America, Italy, and United Kingdom) produced 145/215 (67%) articles. A total of 16 case reports/series from eight countries reported that conjunctivitis can be the initial or the only symptom of COVID-19 infection. Conjunctivitis may occur in the middle phase of COVID-19 illness. A total of 10 hospital-based cross-sectional studies reported that between 0% and 31.6% of COVID-19 patients have conjunctivitis or other ocular conditions, with a pooled prevalence of 5.5% reported in a meta-analysis. Viral RNA was detected in conjunctival swabs of patients with and without ocular manifestations, after resolution of conjunctivitis, after nasopharyngeal swabs turned negative and in retina of deceased COVID-19 patients.
Conclusion: Within 3 months of declaring the COVID-19 pandemic, 215 ophthalmology-focused articles were published in PubMed, concentrating on disease manifestations and transmission. The reported presence of conjunctivitis or other ocular conditions in COVID-19 patients is varied. Clinicians should be alert for ocular involvement in COVID-19 infections and possible ocular transmission even in patients without ocular symptoms.

Keywords
COVID-19, conjunctivitis, manifestation, transmission, publications

Date received: 27 August 2020; accepted: 17 January 2021

Introduction
In December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, China.1 Facilitated by an integrated global economy and modern air travel, the virus quickly spread. On March 11, 2020, COVID-19 (corona-virus disease of 2019) was declared a pandemic by the World Health Organization (WHO).2 As of June 12, 2020, the virus infected about 7.5 million individuals in 212 countries.3 Hundreds of cities and countries around the world went into lockdown in the hope of limiting/stopping viral transmission.
International awareness of COVID-19 has been attributed to Dr. Wenliang Li, an ophthalmologist in Wuhan, China. Ophthalmologists are at high risk of acquiring COVID-19 likely due to a combination of examination proximity and contact with mucous membranes. Ophthalmologists, including the original whistleblower Dr. Wenliang Li, were among the first physicians to die from the virus. Ophthalmologists were among the initial investigators to study the virus and to advise on both treatment and protective measures for physicians, patients, and populations.

This paper summarizes research endeavors by ophthalmologists into COVID-19 and the relevant findings through a systematic review on ophthalmology-focused COVID-19 publications. To place these research endeavors into a larger context, we compared ophthalmology-focused publications to all publications on COVID-19.

**Methods**

**Eligibility criteria, search, data source, and study selection**

All ophthalmology articles on COVID-19 in PubMed were considered eligible and were included in the analyses. This is because our study aims included all ophthalmology research and clinical endeavors against COVID-19. Among identified ophthalmology-focused COVID-19 articles we further manually classified them into eight categories: original data, sharing experience, meta-analysis, review (without meta-analysis), recommendation, guideline, discussion/comment, and editorials. Articles containing original data were further examined in details.

The database LitCovid was searched. LitCovid is a curated literature hub for tracking up-to-date scientific information about the 2019 novel coronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), commonly referred to as COVID-19. It is the most comprehensive resource on this subject, providing a central access to COVID-19 relevant articles in PubMed and updating articles daily. LitCovid has a more sophisticated search function than existing resources. It identifies roughly 35% more relevant articles than do conventional keyword-based searches for entries such as “COVID-19” or “nCOV.”

LitCovid uses a two-step search approach. First, a set of articles are retrieved from PubMed with the query “coronavirus”[All Fields] OR “ncov”[All Fields] OR “cov”[All Fields] OR “2019-nCoV”[All Fields] OR “COVID-19”[All Fields] OR “SARS-CoV-2”[All Fields]. Next, search results are human reviewed and relevant articles identified and curated with assistance from an automated machine-learning and text-classification algorithm. Irrelevant articles are then discarded. Articles are manually assigned by LitCovid group to eight broad categories when applicable: general information, disease mechanism, transmission dynamics, diagnosis, treatment, prevention, case report, and epidemic forecasting.

**Assessment of the quality of the evidence**

The quality of the evidence was assessed for articles investigating ocular involvement in COVID-19 patients, a major concern of this review. Three types of original studies included: case-reports/case series, cross-sectional studies/surveys, and meta-analyses. For case reports and case series, the tool used to evaluate the methodological quality of case reports and case series published by Murad et al. was used. For cross-sectional studies, the checklist recommended by the Agency for Healthcare Research and Quality was applied. For meta-analyses, the measurement tool published by Shea et al was used.

**Data analyses**

This review involved categorical data only. Frequencies and percentages were used in the analyses. Percentages were calculated as the number of occurrences in a subcategory among the sum of all subcategories. The number of publications by country may be influenced by population size and COVID-19 infection rate in a country. We thus calculated the country-specific publication productivity adjusted for population size and COVID-19 infection rates. Data on country population were obtained from Our World in Data. Data on the total number of confirmed COVID-19 cases by country on June 12, 2020 were obtained from Worldometer.
All data used in this study were publicly available thus Institutional Review Board (IRB)/Ethics Committee approval was not required. The study adhered to the tenets of the Declaration of Helsinki.

**Results**

**Total number of publications and by journal and country**

A total of 21,364 articles were registered in LitCovid on June 12, 2020. Of these, 308 were found in the initial search for ophthalmology-focused publications. The abstracts of these 308 articles were reviewed and 93 articles were excluded. Detailed reasons of the exclusion are shown in Figure 1. In all 215 ophthalmology-focused articles were included accounting for 1.01% of all COVID-19 related publications in LitCovid.

Table 1 details the publications breakdown by category. The largest number of all LitCovid publications was in the “Prevention” category, which represents prevention, control, response, and management strategies as defined by LitCovid group. This was also the largest category for those articles with an ophthalmology-focus.
In the category of “Transmission,” 3.3% were from ophthalmology-focused publications. Ophthalmology-focused publications were also found in the categories of disease mechanism, diagnosis, and treatment. There were no ophthalmology-focused publications in the category of “Epidemic Forecasting,” that is, modeling and estimations of COVID-19 spread.

COVID-19 articles were published in 2794 journals. The top five journals by number of publications were “British Medical Journal,” “Journal of Medical Virology,” “Nature,” “Lancet,” and “New England Journal of Medicine” (Table 2). For those with an ophthalmology-focus, 68 journals published COVID-19 articles. The top five journals by number of ophthalmology-focused COVID-19 publications were “Eye (Lond),” “Indian Journal of Ophthalmology,” “Ophthalmology,” “Graefe’s Archive for Clinical and Experimental Ophthalmology,” and “Acta Ophthalmologica” (Table 2).

Authors from 128 countries contributed to all COVID-19 publications and from 25 countries to ophthalmology-focused articles. The top five countries with the most COVID-19 publications were by first author were United States of America (USA), China, Italy, United Kingdom (UK), and India for all articles (Table 2). For ophthalmology-focused publications, China was the most prolific, publishing twice as many as the second highest producing country by first author, India. This was followed closely by USA, Italy, and UK (Table 2). Together these five countries produced 145/215 (67%) of the ophthalmology-focused articles.

Adjusting for population size, Singapore had the greatest number of publications by first author for all COVID-19 publications and from 25 countries to ophthalmology-focused articles. The top five countries with the most COVID-19 publications were by first author were United States of America (USA), China, Italy, United Kingdom (UK), and India for all articles (Table 2). For ophthalmology-focused publications, China was the most prolific, publishing twice as many as the second highest producing country by first author, India. This was followed closely by USA, Italy, and UK (Table 2). Together these five countries produced 145/215 (67%) of the ophthalmology-focused articles.

Overview of ophthalmology-focused publications

Table 3 shows that the largest type of ophthalmology-focused publications contained original data (27.9%), including case-reports/series, cross-sectional studies/surveys, cell/gene studies, post-mortem exams, and new methods of eye protection. The next most frequent type of publications included information on providing in-person care (urgent eye care, emergency surgery, oculoplastic, orbital, and lacrimal care), tele-ophthalmology, resident teaching, and basic science research in ophthalmology during the COVID-19 pandemic. There were 25 editorials published in 15 journals, with 7 (28%) from the journal “Ophthalmology.”

Quality of evidence for studies on ocular manifestations and transmissions in patients with COVID-19

Of the 16 case reports/series assessed, 13 (81.3%) met all reporting requirements (Supplemental Material) and 3 received “unsure” in 1–2 questions from 8 questions assessed. Results of all 16 case reports/series were included in this review. For all cross-sectional studies, the assessment for evaluators being masked to the status of COVID-19 patients was either “No” or “Unclear.” At least 4/11 reporting requirements were met in 10/14 (71.4%) articles on ocular manifestation and transmission (Supplemental Material). Results from these 10 studies were analyzed. The cut-off 4/11 was chosen because the answer “Not applicable” was found in 1–3 items assessed, which mostly related to missing data handling and report. For meta-analyses, 2 studies fulfilled 6 and 7 reporting requirements each from a total 11 questions assessed (Supplemental Material). The third meta-analysis received a “Yes” in 3/11 questions. This study was not included in our detailed analysis.
Ocular manifestations in patients with COVID-19

A total of 14 case reports and 2 case series (consisting of 5 and 7 patients) from China, Italy, France, Canada, USA, Spain, Iran, and Malaysia indicated that conjunctivitis or keratoconjunctivitis as evaluated by ophthalmologists can be the initial symptom of COVID-19 infection, and may be the only presenting feature of COVID-19. Conjunctivitis, episcleritis or orbital emphysema have also been reported to occur during the middle phase of COVID-19 illness, starting on day 7–19 after the onset of COVID-19. Detailed ocular manifestations are shown in Table 4.

Hospital-based cross-sectional studies reveal that between 0% and 31.6% of COVID-19 patients have conjunctivitis, with 75% reporting rates under 4.0%. Two meta-analyses reported that conjunctivitis presented in 1.1% of COVID-19 patients and that the pooled prevalence of conjunctivitis or conjunctival congestion among COVID-19 patients was 5.5% (95% confidence interval 1.6%-9.4%).
### Table 4. Reported ocular manifestations in case-report/series.

| Publication | Country | Patient age and sex | Eye involved | Ocular manifestations |
|-------------|---------|---------------------|--------------|-----------------------|
| Casalino²⁹  | Italy   | 48, Male            | Right eye    | Redness, watery discharge, foreign body sensation, Clinical history and slit lamp examination were consistent with a viral conjunctivitis in the right eye, Ocular manifestations proceeded cough and fever |
| Cheema³⁰    | Canada  | 29, Female          | Right eye    | Photophobia, swollen eyelid, mucous discharge, pain, irritation, Initial presentation: 1–12+ conjunctival injection, 3+ follicles, 1 small pseudodendrite in the inferior temporal cornea, 8 small subepithelial infiltrates with overlying epithelial defects at the superior temporal limbus. Fundus exam unremarkable with no inflammation Visual acuity 20/20 OU. Diagnosed with herpetic keratoconjunctivitis, 2 days later: a tender right preauricular node, 2+ conjunctival injection, numerous subepithelial infiltrates with overlying epithelial defects. Visual acuity 20/20 OU Diagnosed with epidemic keratoconjunctivitis, 3 days after initial presentation: worsening symptoms and vision decline. Visual acuity 20/30 in right eye. Follicular conjunctivitis with 2+ conjunctival injection and over 50 discrete subepithelial infiltrates with overlying epithelial defects spread diffusely through the entire cornea |
| Chen³⁶      | China   | 30, Male            | Both eyes    | Redness and foreign body sensation in both eyes 13 days after onset of sore throat and diarrhea and 6 days after nasopharyngeal swabs tested positive for SARS-CoV-2, Slit lamp examination identified bilateral moderate conjunctival injection, watery discharge, inferior palpebral conjunctival follicles and tender palpable preauricular lymph nodes, 1 day after redness and foreign body sensation, the conjunctival swab specimens positive for SARS-CoV-2 |
| Colavita⁴⁰  | Italy   | 65, Female          | Both eyes    | Presented with nonproductive cough, sore throat, coryza, and bilateral conjunctivitis (severe conjunctival hyperemia, chemosis, epiphora), Sputum positive for SARS-CoV-2 on day of admission, Ocular swab positive for SARS-CoV-2 on day 3 of admission and remained positive until day 21 of admission, Ocular swab positive again on day 27, 5 days after it became undetectable |
| Daruich³²   | Author in France, patient in Argentina | 27, Male | Left eye | Redness, foreign body sensation, Eyelid edema and moderate conjunctival hyperemia, Intense headache, fever, cough, and severe dyspnea following eye complaints, Nasopharyngeal swab positive for SARS-CoV-2 |
| Khavand³¹   | Iran    | 65, Male            | Not stated   | Burning eye, mucoid discharge, and follicular conjunctivitis diagnosed as viral conjunctivitis, 2 days later patient presented to emergency room with a sudden-onset fever of 101.4°F, dry cough, and shortness of breath, Nasopharyngeal swab and subsequent conjunctival confirmed diagnosis of COVID-19 |
| Mendez Mangana³⁷ | Spain | 31, Female | Left eye | Red eye, foreign-body sensation, epiphora, and photophobia without impaired vision 7 days after cough, myalgia, and nasopharyngeal swab positive for COVID-19 infection, Slightly elevated epibulbar area with hyperemia at the inferotemporal sector without fluorescein defect consistent with nodular episcleritis |
| Navel³⁸     | France  | 63, Male            | Both eyes    | Conjunctival hyperemia 17 days after flu-like symptoms with bronchial secretions positive for SARS-CoV-2, Day 19 ocular exam in ICU found petechias and tarsal hemorrhages, mucous filaments, and tarsal pseudomembranous, Slit lamp and other evaluations of anterior segment complications (such as uveitis or intraocular hypertension) not performed due to intubation |

(Continued)
Exam of the posterior segment revealed no vitreous inflammation or retinal abnormalities
Day 20 tears and conjunctival scrapings and swab tested negative for SARS-CoV-2
Diagnosed with pseudomembranous and hemorrhagic conjunctivitis related to SARS-CoV-2
7 cases with oculomotor paresis, SARS-CoV-2 positive in 3 cases
Respiratory symptoms preceded diplopia by approximately 2 weeks in all cases
Asymptomatic when oropharyngeal and nasal swab tested positive for COVID-19
Injected, irritated, and swollen eyes 18 days after COVID-19 testing positive
Transparent serous secretions, conjunctival chemosis, pseudomembranes of fibrin, and inflammatory cells on the tarsal conjunctiva accompanied by preauricular lymph nodes and enlarged submaxillary nodes
Diagnosed with severe viral conjunctivitis
Conjunctival hyperemia, epiphora, discharge, and photophobia
Diagnosed with acute conjunctivitis
None of these patients displayed fever, general malaise, or respiratory symptoms.
Nasopharyngeal swab positive for all of 5
10-day history of fever, cough, and progressive dyspnea with positive COVID-19 test
ICU patient, subcutaneous emphysema extended from the chest to the face, unilaterally in the conjunctiva, and bilaterally around the eyelids
Asymptomatic with nasopharyngeal swabs positive for SARS-CoV-2
Conjunctival congestion and eyelid erythema and swelling 7 days after positive SARS-CoV-2 test
Diagnosed with conjunctivitis and eyelid dermatitis
Redness (started in left eye for 1 day and to right eye the next day), watery eyes, and mild swelling over both eyelids
Bilateral conjunctivae hyperemic
Oropharyngeal and nasopharyngeal swab testing positive for SARS-CoV-2 8 days after ocular complaints
Denied any respiratory symptoms or fever before or after SARS-CoV-2 testing positive
Fever, fatigue, and cough
Sputum and nasopharyngeal swab positive for SARS-CoV-2
No symptoms and signs of conjunctivitis
Obstruction of lacrimal duct in left eye with mild tearing and without any secretion
Nasopharyngeal swabs positive for 22 days
Eye swabs continuously positive for 2 weeks after nasopharyngeal swabs turned negative
Itchy eyes, followed by dizziness, fever, nasal-congestion and rhinorrhea
Respiratory-sample testing positive for SARS-CoV-2 4 days after ocular symptoms
Infected 7 additional patients (laboratory-confirmed SARS-CoV-2-infection) before obtaining the positive result for SARS-CoV-2
Ocular transmissions in patients with COVID-19

Positive conjunctival swabs for COVID-19 were reported in case reports of patients with clinically manifested conjunctivitis. In patients after the conjunctivitis had resolved for 1 week, or 11 days after nasopharyngeal swabs turned negative. Examining hospital-based patients revealed that positive conjunctival swabs can be found in patients with and without ocular manifestations. The reported positive rate ranged from 0% to 16.7% in patients with conjunctivitis or other ocular abnormalities and from 0% to 6.1% in those without conjunctivitis. A post-mortem study documented that viral RNA was detected in the retina of 3/14 deceased COVID-19 patients. CELL/GENE studies reported that the co-expression of the SARS-CoV-2 receptor (i.e. ACE2) was detected in human adult conjunctival, limbal, and corneal epithelium, suggesting the human conjunctival and corneal epithelium may provide an additional entry portal for SARS-CoV-2. However, no significant expression of the ACE2 in conjunctival samples on the mRNA and protein levels was reported.

Discussion

We report that 3 months after the COVID-19 pandemic was declared, ophthalmologists/researchers from 25 countries contributed 215 articles in 68 journals on the subject. These articles centered on understanding the ocular manifestations and transmission of COVID-19 infection and how to manage safe eye care, teaching, and research during the outbreak. Data from 16 case reports/series from eight countries indicate that conjunctivitis can be the initial or only symptom of COVID-19 infection. Conjunctivitis can occur 1–3 weeks after the onset of COVID-19. About 10 studies of hospital-based patients found the presence of conjunctivitis or other ocular abnormalities in patients affected with COVID-19 varied, ranging from 0% to 31.6%. All these 10 studies were derived from single hospital-based clinic records. The possibility of selected samples cannot be ruled out in producing the large variation. A meta-analysis showed a 5.5% (95% confidence interval 1.6%-9.4%) pooled prevalence rate of conjunctivitis or conjunctival congestion among COVID-19 patients. Positive conjunctival swabs have been reported in patients with and without conjunctivitis, including positive swabs 7 days after resolution of the conjunctivitis. Of concern to ophthalmologists is the report that conjunctival swabs can test positive for up to 11 days after nasopharyngeal swabs have turned negative. Viral RNA has been reported in the retina of deceased COVID-19 patients. These results demonstrate that conjunctivitis or other ocular abnormalities may be a presenting symptom of COVID-19 infection and the eye can be a potential source of COVID-19 transmission, even after nasopharyngeal swabs have turned negative. These findings have implications to healthcare providers, policy makers and the public regarding COVID-19 management and prevention.

At the beginning of the COVID-19 outbreak, the disease was thought to be transmitted through respiratory droplets with direct contact. The main impact of this disease was thought to be on the respiratory system. The very first person who alerted that there could be ocular involvement in COVID-19 was a member of the expert task force who visited COVID-19 patients in Wuhan, China. Despite being fully gowned with protective equipment including N95 mask, he was infected by the virus with the first symptom being unilateral conjunctivitis, followed by development of fever. Since then, “conjunctivitis” has been linked to COVID-19. To date, observations from case reports and cross-sectional studies originating from multiple countries lend support to this suspicion. However, lack of a control group from non COVID-19 individuals makes us difficult to know if conjunctivitis presented more frequently in COVID-19 patients.

Although the viral detection rate in conjunctival and tear samples seems to be low (0% to 16.7% in patients with conjunctivitis or other ocular abnormalities), the risk of ocular transmission remains a possibility, especially when considering the potential that negative conjunctival swab test results may arise from missed window of best sampling time and imperfect test sensitivity. Overall, results of this review offer two implications for clinical management of COVID-19. Firstly, conjunctivitis can be the initial or the only symptom of COVID-19 infection. This suggests that ophthalmologists and other healthcare providers such as emergency room physicians and family physicians should be on alert and practise appropriate self-protection (including eye protection) during the examination and treatment of new patients with ocular complaints. Secondly, when dealing with patients with diagnosed COVID-19 but without ocular complaints or those patients with nasopharyngeal swabs having turned negative, healthcare providers including ophthalmologists should be mindful of the possibility of viral transmission from the eye as positive conjunctival swabs have been reported in COVID-19 patients without conjunctivitis, and even in patients 11 days after nasopharyngeal swabs turned negative. Recently, a report from Italy identified for the first time that SARS-CoV-2 RNA was identified in a pediatric patient with very mild ocular complaints. This Italian report not only reinforces the findings of this review but emphasizes the above clinical implications offered should be considered when dealing with adult and pediatric patients.

In COVID-19 patients, the conjunctivitis rate and the presence of other ocular abnormalities (0%-31.6%) seems to be greater than the detection rate of SARS-CoV-2
observed from conjunctival samples by means of laboratory analysis (0%-16.7%). One possible explanation is that conjunctivitis and other ocular abnormalities may be caused by SARS-CoV-2 as well as by viruses, bacteria, and factors other than SARS-CoV-2. For example, reports have shown that COVID-19 patients in intensive care units (ICU) treated with continuous positive airway pressure (CPAP) are more likely to have ocular abnormalities than those not treated with CPAP (52.5% versus 30.8%, p<0.01), due to air leaks from the CPAP mask. Such CPAP treatment may result in dry eyes causing ocular discomfort.66 Therefore, if conjunctival swabs are SARS-CoV-2 negative, ophthalmologists should look for other potential factors that can cause ocular signs and symptoms in COVID-19 patients, particularly in ICU patients.

Most of the current studies on ocular involvement in COVID-19 are based on case reports/series and hospital-based cross-sectional studies, which are considered level 4 evidence by the Oxford Centre for Evidence-based Medicine.67 This is not ideal, however, given that we are dealing with a novel disease with many unknown clinical features, these early reports have contributed to advancing our knowledge on COVID-19’s clinical presentation and transmission and have provided important information to clinicians and decision-makers regarding the need for appropriate eye protection. Other examples of level 4 evidence contributing to improved disease understanding are found in the AIDS and sickle cell disease literature.68–70

To date COVID-19 has been reported in over 200 countries.3 Ophthalmologists from 25 countries have contributed to the global understanding of the pandemic. The collective efforts of ophthalmologists demonstrate that ocular manifestations in COVID-19 patients occur in different ethnic populations, such as China, Italy, France, Canada, USA, Spain, Iran, and Malaysia.

Journal editors may play an important role encouraging and discouraging COVID-19 publications in their journals.71 We do not know if the top five COVID-19 publication journals mainly reflect the journal editors’ choice. However, 7/25 (28%) editorials in ophthalmology-focused articles were from “Ophthalmology,” which ranks number 3 by journal in ophthalmology-focused publications.

This study has limitations. First, article citations were not evaluated due to the short time period since COVID-19 identification and the lag between publications and citations. Second, the country of origin was assigned based on the first author affiliation only. Although this methodology has been widely used in previous publications,9–32 this may not accurately capture the country of all coauthors. Third, only articles registered in LitCovid were included.

Study strengths include that all peer-reviewed publications in knowledge creation (e.g. case reports, post-mortem exams, and patient surveys) and knowledge dissemination (e.g. reviews and guidelines) were reviewed. The quality of the evidence on ocular issues in COVID-19 was assessed using published evaluation tools before summary.

**Conclusion**

This systematic review of ophthalmology-focused publications on COVID-19 indicates that ophthalmologists/researchers from 25 countries have published 215 articles in 68 journals within 3 months of the WHO declaration of the pandemic. These publications support the initial suspicion of ocular manifestation and possible transmission in COVID-19 infections and serve to inform best clinical practices. However, it is unknown if the frequency of conjunctivitis in COVID-19 patients differs from that in non-COVID-19 individuals. Future population-based studies are needed to overcome the drawback of selected patient samples from case reports and single hospital-based records.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Ya-Ping Jin https://orcid.org/0000-0002-6348-0895

**Supplemental material**

Supplemental material for this article is available online.

**References**

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506.
2. World Health Organization. Archived: WHO timeline - COVID-19, https://www.who.int/news-room/detail/27-04-2020-who-timeline-covid-19 (accessed 30 June 2020).
3. Our World in Data. Data on COVID-19 (coronavirus) by different world regions during a 9-year period (1995-2003). https://github.com/owid/covid-19-data/tree/master/public/data (accessed 30 June 2020).
4. Olivia Li JP, Shantha J, Wong TY, et al. Preparedness among ophthalmologists: during and beyond the COVID-19 pandemic. Ophthalmology 2020; 127(5): 569–572.
5. Qiao C, Zhang H, He M, et al. Symptomatic COVID-19 in eye professionals in Wuhan, China. Ophthalmology 2020; 127(9): 1268–1270.
6. NIH National Library of Medicine. LitCovid, https://www.ncbi.nlm.nih.gov/research/coronavirus/ (accessed 30 June 2020).
7. Chen Q, Allot A and Lu Z. Keep up with the latest coronavirus research. Nature 2020; 579(7798): 193.
8. Python. https://www.python.org/downloads/ (accessed 3 July 2020).
9. Bliziotis IA, Paraschakis K, Vergidis PI, et al. Worldwide trends in quantity and quality of published articles in the field of infectious diseases. BMC Infect Dis 2005; 5: 16.
10. Falagas ME, Papastamatakis PA and Bliziotis IA. A bibliometric analysis of research productivity in parasitology by different world regions during a 9-year period (1995-2003). BMC Infect Dis 2006; 6: 56.
11. Skevaki CL, Koliaraki V, Papadopoulos NG, et al. Global research productivity in allergy. *J Investig Allergol Clin Immunol* 2011; 21(2): 156–158.

12. Tsui BC, Li LX, Ma V, et al. Declining randomized clinical trials from Canadian anesthesia departments? *Can J Anaesth* 2006; 53(3): 226–235.

13. Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. *BMJ Evid Based Med* 2018; 23(2): 60–63.

14. The Agency for Healthcare Research and Quality. Methodology checklist for cross-sectional study, https://www.ncbi.nlm.nih.gov/books/NBK35156/ (accessed 15 July 2020).

15. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMJ Med Res Methodol* 2007; 7: 10.

16. Worldometer. Countries in the world by population, https://www.worldometers.info/world-population/population-by-country/ (2020, accessed 6 July 2020).

17. ISI Web of Knowledge. ISI web of knowledge, http://isiwebofknowledge.com/; 2019.

18. Borrelli E, Sacconi R, Querques L, et al. Taking the right measures to control COVID-19 in ophthalmology: the experience of a tertiary eye care referral center in Italy. *Eye (Lond)* 2020; 34(7): 1175–1176.

19. Jun ISY, Hui KKo and Songbo PZ. Perspectives on coronavirus disease 2019 control measures for ophthalmology clinics based on a Singapore center experience. *JAMA Ophthalmol* 2020; 138(5): 435–436.

20. Lai THT, Tang EWH, Chau SKY, et al. Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong. *Graefes Arch Clin Exp Ophthalmol* 2020; 258(5): 1049–1055.

21. Du H, Zhang M, Zhang H, et al. Practical experience on emergency ophthalmic surgery during the prevalence of COVID-19. *Graefes Arch Clin Exp Ophthalmol* 2020; 258(8): 1831–1833.

22. O’Rourke M, Hardy T, Au A, et al. Practical experience on emergency ophthalmic surgery during COVID-19-a Hong Kong perspective. *Graefes Arch Clin Exp Ophthalmol* 2020; 258(12): 2867–2868.

23. Tang EWH, Wong DHT, Chan YYY, et al. Emergency ophthalmic surgeries during COVID-19-a Hong Kong perspective. *Graefes Arch Clin Exp Ophthalmol* 2020; 258(12): 2867–2868.

24. Das AV, Rani PK and Vaddavalli PK. Tele-consultations and electronic medical records driven remote patient care: responding to the COVID-19 lockdown in India. *Indian J Ophthalmol* 2020; 68(6): 1007–1012.

25. Shen HG, Wang CY, Chen HJ, et al. Tele-ophthalmology amid COVID-19 pandemic-Hong Kong experience. *Graefes Arch Clin Exp Ophthalmol*. Epub ahead of print May 2020. DOI: 10.1007/s00417-020-04753-1.

26. Shih KC, Chan JC, Chen JY, et al. Ophthalmic clinical skills teaching in the time of COVID-19: a crisis and opportunity. *Med Educ* 2020; 54(7): 663–664.

27. Chen Y, Jin YL, Zhu LJ, et al. The network investigation on knowledge, attitude and practice about COVID-19 of the residents in Anhui Province. *Zhonghua Yu Fang Yi Xue Za Zhi* 2020; 54(4): 367–373.

28. Nassisi M, Audo I, Zeitz C, et al. Impact of the COVID-19 lockdown on basic science research in ophthalmology: the experience of a highly specialized research facility in France. *Eye (Lond)* 2020; 34(7): 1187–1188.

29. Casalino G, Monaco G, Di Sarro PP, et al. Coronavirus disease 2019 presenting with conjunctivitis as the first symptom. *Eye (Lond)* 2020; 34(7): 1235–1236.

30. Cheema M, Aghazadeh H, Nazarali S, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). *Can J Ophthalmol* 2020; 55(4): e125–e129.

31. Khavandi S, Tabibzadeh E, Naderan M, et al. Coronavirus disease-19 (COVID-19) presenting as conjunctivitis: a typically high-risk during a pandemic. *Cont Lens Anterior Eye* 2020; 43(3): 211–212.

32. Daruich A, Martin D and Bremond-Gignac D. Ocular manifestation as first sign of coronavirus disease 2019 (COVID-19): interest of telediagnosis during the pandemic context. *J Fr Ophtalmol* 2020; 43(5): 389–391.

33. Wu P, Liang L, Chen C, et al. A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis. *Graefes Arch Clin Exp Ophthalmol* 2020; 258(7): 1565–1566.

34. Scalinci SZ and Trovato Battagliola E. Conjunctivitis can be the only presenting sign and symptom of COVID-19. *IDCases* 2020; 20: e00774.

35. Ying NY, Idris NS, Muhamad R, et al. Coronavirus disease 2019 presenting as conjunctivitis. *Korean J Fam Med*. Epub ahead of print June 2020. DOI: 10.4082/kjfm.20.0090.

36. Chen L, Liu M, Zhang Z, et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. *Br J Ophthalmol* 2020; 104(6): 748–751.

37. Mendez Mangana C, Barraquer Kargacin A and Barraquer RI. Episcleritis as an ocular manifestation in a patient with COVID-19. *Acta Ophthalmol* 2020; 98(8): e1056–e1057.

38. Navel V, Chiambaretta F and Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid detection in tear and conjunctival secretions of a non-conjunctivitis patient with only symptoms of conjunctivitis and eyelid dermatitis. *Acta Ophthalmol* 2020; 98(8): e1056–e1057.

39. Colavita F, Lapa D, Carletti F, et al. SARS-CoV-2 isolation on knowledge, attitude and practice about COVID-19 of the residents in Anhui Province. *Zhonghua Yu Fang Yi Xue Za Zhi* 2020; 54(4): 367–373.

40. Nassisi M, Audo I, Zeitz C, et al. Impact of the COVID-19 lockdown on basic science research in ophthalmology: the experience of a highly specialized research facility in France. *Eye (Lond)* 2020; 34(7): 1187–1188.

41. Casalino G, Monaco G, Di Sarro PP, et al. Coronavirus disease 2019 presenting with conjunctivitis as the first symptom. *Eye (Lond)* 2020; 34(7): 1235–1236.

42. Cheema M, Aghazadeh H, Nazarali S, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). *Can J Ophthalmol* 2020; 55(4): e125–e129.

43. Khavandi S, Tabibzadeh E, Naderan M, et al. Coronavirus disease-19 (COVID-19) presenting as conjunctivitis: a typically high-risk during a pandemic. *Cont Lens Anterior Eye* 2020; 43(3): 211–212.

44. Daruich A, Martin D and Bremond-Gignac D. Ocular manifestation as first sign of coronavirus disease 2019 (COVID-19): interest of telediagnosis during the pandemic context. *J Fr Ophtalmol* 2020; 43(5): 389–391.

45. Wu P, Liang L, Chen C, et al. A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis. *Graefes Arch Clin Exp Ophthalmol* 2020; 258(7): 1565–1566.

46. Scalinci SZ and Trovato Battagliola E. Conjunctivitis can be the only presenting sign and symptom of COVID-19. *IDCases* 2020; 20: e00774.

47. Ying NY, Idris NS, Muhamad R, et al. Coronavirus disease 2019 presenting as conjunctivitis. *Korean J Fam Med*. Epub ahead of print June 2020. DOI: 10.4082/kjfm.20.0090.

48. Chen L, Liu M, Zhang Z, et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. *Br J Ophthalmol* 2020; 104(6): 748–751.

49. Mendez Mangana C, Barraquer Kargacin A and Barraquer RI. Episcleritis as an ocular manifestation in a patient with COVID-19. *Acta Ophthalmol* 2020; 98(8): e1056–e1057.

50. Navel V, Chiambaretta F and Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid detection in tear and conjunctival secretions of a non-conjunctivitis patient with only symptoms of conjunctivitis and eyelid dermatitis. *Acta Ophthalmol* 2020; 98(8): e1056–e1057.

51. Colavita F, Lapa D, Carletti F, et al. SARS-CoV-2 isolation on knowledge, attitude and practice about COVID-19 of the residents in Anhui Province. *Zhonghua Yu Fang Yi Xue Za Zhi* 2020; 54(4): 367–373.
44. Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16–23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study. J Infect 2020; 80(6): e1–e13.

45. Guemes-Villahoz N, Burgos-Blasco B, Arribi-Vilela A, et al. SARS-CoV-2 RNA detection in tears and conjunctival secretions of COVID-19 patients with conjunctivitis. J Infect 2020; 81(3): 452–482.

46. Bostanci Ceran B and Ozates S. Ocular manifestations of coronavirus disease 2019. Graefes Arch Clin Exp Ophthalmol 2020; 258(9): 1959–1963.

47. Karimi S, Arabi A, Shahraki T, et al. Detection of severe acute respiratory syndrome coronavirus-2 in the tears of patients with coronavirus disease 2019. Eye (Lond) 2020; 34(7): 1220–1223.

48. Xia J, Tong J, Liu M, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol 2020; 92(6): 589–594.

49. Xie HT, Jiang SY, Xu KK, et al. SARS-CoV-2 in the ocular surface of COVID-19 patients. Eye Vis (Lond) 2020; 7: 23.

50. Kumar K, Prakash AA, Gangasagara SB, et al. Presence of viral RNA of SARS-CoV-2 in conjunctival swab specimens of COVID-19 patients. Indian J Ophthalmol 2020; 68(6): 1015–1017.

51. Lan QQ, Zeng SM, Liao X, et al. A special on epidemic prevention and control: screening for novel coronavirus related conjunctivitis among the patients with coronavirus disease 2019. Zhonghua Yan Ke Za Zhi 2020; 56(5): 433–437.

52. Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020; 138(5): 575–578.

53. Chen L, Deng C, Chen X, et al. Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study. Acta Ophthalmol 2020; 98(8): e951–e959.

54. Hong N, Yu W, Xia J, et al. Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19. Acta Ophthalmol. Epub ahead of print April 2020. DOI: 10.1111/aos.14445.

55. Loffredo L, Pacella F, Pacella E, et al. Conjunctivitis and COVID-19: a meta-analysis. J Med Virol 2020; 92(9): 1413–1414.

56. Ulhaq ZS and Soraya GV. The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/liquid. Graefes Arch Clin Exp Ophthalmol 2020; 258(6): 1351–1352.

57. Zhou Y, Duan C, Zeng Y, et al. Ocular findings and proportion with conjunctival SARS-COV-2 in COVID-19 patients. Ophthalmology 2020; 127(7): 982–983.

58. Casagrande M, Fitzek A, Puschel K, et al. Detection of SARS-CoV-2 in human retinal biopsies of deceased COVID-19 patients. Ocul Immunol Inflamm 2020, 28(5): 721–725.

59. Collin J, Queen R, Zerti D, et al. Co-expression of SARS-CoV-2 entry genes in the superficial adult human conjunctival, limbal and corneal epithelium suggests an additional route of entry via the ocular surface. Ocul Surf. Epub ahead of print June 2020. DOI: 10.1016/j.jtos.2020.05.013.

60. Grajewski RS, Rokohl AC, Becker M, et al. A missing link between SARS-CoV-2 and the eye?: ACE2 expression on the ocular surface. J Med Virol. Epub ahead of print June 2020. DOI: 10.1002/jmv.26136.

61. Ma D, Chen CB, Jhanji V, et al. Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea. Eye (Lond) 2020; 34(7): 1212–1219.

62. Lange C, Wolf J, Auw-Haedrich C, et al. Expression of the COVID-19 receptor ACE2 in the human conjunctiva. J Med Virol 2020; 92(10): 2081–2086.

63. Yuen KS, Chan WM, Fan DS, et al. Ocular screening in severe acute respiratory syndrome. Am J Ophthalmol 2004; 137(4): 773–774.

64. Dai X. Peking University Hospital Wang Guangfa disclosed treatment status on Weibo and suspected infection without wearing goggles, http://www.bjnews.com.cn/news/2020/01/23/678189.html (23 January 2020, accessed 30 June 2020).

65. Quaranta L, Rovida F, Riva I, et al. Identification of SARS-CoV-2 RNA in the conjunctival swab of an Italian pediatric patient affected with COVID-19: a case report. Eur J Ophthalmol. Epub ahead of print December 2020. DOI: 10.1177/1120672120977822.

66. Cavalleri M, Brambati M, Starace V, et al. Ocular features and associated systemic findings in SARS-CoV-2 infection. Ocul Immunol Inflamm 2020; 28(6): 916–921.

67. The Centre for Evidence-Based Medicine Develops, Promotes and Disseminates Better Evidence for Healthcare. Oxford centre for evidence-based medicine – levels of evidence, https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ (March 2009, accessed 13 July 2020).

68. Centers for Disease Control. Pneumocystis pneumonia—Los Angeles. Morb Mortal Wky Rep 1981; 30(21): 250–252.

69. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med 1910; VII(5): 517–521.

70. Kempen JH. Appropriate use and reporting of uncontrolled case series in the medical literature. Am J Ophthalmol 2011; 151(1): 7–10, e1.

71. Gittinger JW Jr. Survey of ophthalmology in the time of COVID-19. Surv Ophthalmol 2020; 65(5): 495.